Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP1295 | DOI: 10.1530/endoabs.49.EP1295

ECE2017 Eposter Presentations: Thyroid Thyroid (non-cancer) (260 abstracts)

Treatment of toxic multinodular goiter with 131 radioactive iodine – effects in volume reduction, thyroid function and autoimmunity

Catarina Roque 1 , Francisco Sousa Santos 1 , Tania Pilli 2 & Furio Pacini 2


1Endocrine Unit, Hospital de Egas Moniz, C.H.L.O. E.P.E., Lisbon, Portugal; 2Endocrine Unit, University of Siena, Siena, Italy.


Abstract: Radioiodine is a definite treatment option for toxic goiter. We have evaluated volume reduction, function and autoimmunity outcomes with a 15 mCi fixed regimen. Patients with at least one US evaluation before and after Iodine-131 therapy and with at least one year of follow-up were included. TSH, free-T4, antibodies and goiter volume before and yearly after Iodine-131 treatment were analysed for the length of the entire follow-up. The total 151 patients, 72.6% females, had a mean follow-up of 6.2 (1–12) years. At the time of treatment, the mean age was 68.8 years and the initial goiter volume 48.9 (8–255.7) ml, with no statistical difference between sexes. Increased volume was observed in 96.5% females and 91.7% males and there were 10.6% in hyperthyroidism and 89.4% in subclinical hyperthyroidism. The mean percentage volume reduction in the first year was 29.8% which represents 14.7 ml with a Pearson coefficient of correlation with initial volume of 0.058. During the following years mean reductions of 19.7, 15.8, 9.7, 5.8 and 1.4% were observed. Absolute volume reductions were maximal at the 3rd and 4th years representing mean reductions of 50 and 52%. Initial volume, TSH and age could not produce an explicative model for the percentage of reduced volume. Euthyroidism was achieved in 60.9% patients, subclinical hyperthyroidism in 8.6% and hypothyroidism in 26.5% of which 23.8% were subclinical. Hypothyroidism was related significantly with initial volume (P<0.001) and maximal percentage of reduction (P=0.012). The development of new detectable anti-thyroid antibodies was identified in 5 patients (6.9%), the result being above cut-off in none of them. New anti-TSH-receptor antibodies developed in 4 (5.5%) patients 1–3 years post-treatment. With 15 mCi, all patients experienced volume reduction in the first years after treatment, achieving means above 50% at the 3rd year, most were rendered euthyroid and developed no auto-immunity.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.